Last reviewed · How we verify
Basal insulin analogues
Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control.
Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Basal insulin analogues |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Basal insulin analogue |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Basal insulin analogues are engineered insulin molecules designed to have a prolonged duration of action (typically 24 hours or longer) and a relatively flat pharmacokinetic profile. They mimic the body's natural basal insulin secretion by maintaining consistent insulin levels throughout the day and night, reducing hepatic glucose production and facilitating peripheral glucose uptake. Common basal analogues from Novo Nordisk include insulin glargine (Lantus, Basaglar) and insulin degludec (Tresiba).
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes (PHASE4)
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (PHASE3)
- Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (PHASE4)
- Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin (NA)
- A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (PHASE4)
- The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (PHASE3)
- Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (PHASE4)
- Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basal insulin analogues CI brief — competitive landscape report
- Basal insulin analogues updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI